{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:56Z","timestamp":1776988796582,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Threshold Pharmaceuticals, Inc."},{"name":"National Comprehensive Cancer Network (NCCN) Oncology Research Program"},{"name":"Novartis Pharmaceuticals Corporation (US)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3256-2","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T16:00:42Z","timestamp":1488038442000},"page":"611-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase I study of pazopanib plus TH-302 in advanced solid tumors"],"prefix":"10.1007","volume":"79","author":[{"given":"Richard F.","family":"Riedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellen L.","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope E.","family":"Uronis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard C.","family":"Blobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel N.","family":"Rushing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy C.","family":"Arrowood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,25]]},"reference":[{"key":"3256_CR1","first-page":"297","volume":"435","author":"JM Brown","year":"2007","unstructured":"Brown JM (2007) Tumor hypoxia in cancer therapy. Methods Enzymol 435:297\u2013321","journal-title":"Methods Enzymol"},{"key":"3256_CR2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10555-010-9224-5","volume":"29","author":"EC Finger","year":"2010","unstructured":"Finger EC, Giaccia AJ (2010) Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 29:285\u2013293","journal-title":"Cancer Metastasis Rev"},{"key":"3256_CR3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ejca.2010.02.020","volume":"46","author":"F Azam","year":"2010","unstructured":"Azam F, Mehta S, Harris AL (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46:1323\u20131332","journal-title":"Eur J Cancer"},{"key":"3256_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cytogfr.2009.11.003","volume":"21","author":"N Ferrara","year":"2010","unstructured":"Ferrara N (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21:21\u201326","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Suppl 3","key":"3256_CR5","first-page":"4","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Int Soc Cell 69(Suppl 3):4\u201310","journal-title":"Int Soc Cell"},{"key":"3256_CR6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01874","volume":"425","author":"P Staller","year":"2003","unstructured":"Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307\u2013311","journal-title":"Nature"},{"key":"3256_CR7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.20030267","volume":"198","author":"T Schioppa","year":"2003","unstructured":"Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G, Sica A (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391\u20131402","journal-title":"J Exp Med"},{"key":"3256_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague J (2008) TGFbeta in cancer. Cell 134:215\u2013230","journal-title":"Cell"},{"key":"3256_CR9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220\u2013231","journal-title":"Cancer Cell"},{"key":"3256_CR10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232\u2013239","journal-title":"Cancer Cell"},{"key":"3256_CR11","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-09-0095","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Kerbel RS (2009) Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15:5020\u20135025","journal-title":"Clin Cancer Res"},{"key":"3256_CR12","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","volume":"104","author":"JM Ebos","year":"2007","unstructured":"Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104:17069\u201317074","journal-title":"Proc Natl Acad Sci USA"},{"key":"3256_CR13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-09-2533","volume":"70","author":"PG Nikolinakos","year":"2010","unstructured":"Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV (2010) Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70:2171\u20132179","journal-title":"Cancer Res"},{"key":"3256_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.16.2.239","volume":"16","author":"RS Herbst","year":"2007","unstructured":"Herbst RS, Heymach JV, O\u2019Reilly MS, Onn A, Ryan AJ (2007) Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239\u2013249","journal-title":"Expert Opin Investig Drugs"},{"key":"3256_CR15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1535-7163.MCT-07-0568","volume":"7","author":"P Beaudry","year":"2008","unstructured":"Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J (2008) Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7:418\u2013424","journal-title":"Mol Cancer Ther"},{"key":"3256_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","volume":"28","author":"S Kopetz","year":"2010","unstructured":"Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453\u2013459","journal-title":"J Clin Oncol"},{"key":"3256_CR17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","volume":"6","author":"RK Jain","year":"2009","unstructured":"Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327\u2013338","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3256_CR18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","volume":"103","author":"ER Gerstner","year":"2011","unstructured":"Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT (2011) Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing antiepileptic drugs and standard radiation and temozolomide. J Neurooncol 103(2):325\u2013332","journal-title":"J Neurooncol"},{"key":"3256_CR19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2009.22.4279","volume":"28","author":"EO Hanrahan","year":"2010","unstructured":"Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV (2010) Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and\/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28:193\u2013201","journal-title":"J Clin Oncol"},{"key":"3256_CR20","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1158\/1078-0432.CCR-08-2568","volume":"15","author":"EO Hanrahan","year":"2009","unstructured":"Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15:3600\u20133609","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3256_CR21","doi-asserted-by":"crossref","first-page":"20122021","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012\u20132021","journal-title":"Mol Cancer Ther"},{"issue":"6560","key":"3256_CR22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","volume":"379","author":"TG Graeber","year":"1996","unstructured":"Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88\u201391","journal-title":"Nature"},{"issue":"8","key":"3256_CR23","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1158\/0008-5472.CAN-10-4049","volume":"71","author":"Q Chang","year":"2011","unstructured":"Chang Q, Jurisica I, Do T, Hedley DW (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 71(8):3110\u20133120","journal-title":"Cancer Res"},{"key":"3256_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2:38\u201347","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"3256_CR25","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1158\/0008-5472.CAN-14-2598","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, Koti M, Siemens DR, Graham CH (2014) Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res 74(24):7185\u20137190","journal-title":"Cancer Res"},{"issue":"4","key":"3256_CR26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/15384047.2016.1139268","volume":"17","author":"JD Sun","year":"2016","unstructured":"Sun JD, Ahluwalia D, Liu Q, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP (2016) Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. Cancer Biol Ther 17(4):371\u2013380","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3256_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cam4.599","volume":"5","author":"V Liapis","year":"2016","unstructured":"Liapis V, Zinonos I, Labrinidis A, Hay S, Ponomarev V, Panagopoulos V, Zysk A, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A (2016) Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Med 5(3):534\u2013545. doi: 10.1002\/cam4.599","journal-title":"Cancer Med"},{"issue":"7","key":"3256_CR28","first-page":"2139","volume":"5","author":"JD Sun","year":"2015","unstructured":"Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP (2015) Combination tre2atment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. Am J Cancer Res 5(7):2139\u20132155 (eCollection 2015)","journal-title":"Am J Cancer Res"},{"issue":"3","key":"3256_CR29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/15384047.2014.1003005","volume":"16","author":"JD Sun","year":"2015","unstructured":"Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP (2015) Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther 16(3):438\u2013449","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"3256_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2014.11.020","volume":"357","author":"V Liapis","year":"2015","unstructured":"Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A (2015) Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Lett 357(1):160\u2013169. doi: 10.1016\/j.canlet.2014.11.020 (Epub 2014 Nov 15)","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"3256_CR31","first-page":"50","volume":"80","author":"KN Ganjoo","year":"2011","unstructured":"Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP (2011) A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Int Soc Cell 80(1\u20132):50\u201356","journal-title":"Int Soc Cell"},{"issue":"29","key":"3256_CR32","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","volume":"32","author":"SP Chawla","year":"2014","unstructured":"Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN (2014) Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 32(29):3299\u20133306","journal-title":"J Clin Oncol"},{"issue":"13","key":"3256_CR33","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","volume":"33","author":"MJ Borad","year":"2015","unstructured":"Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP (2015) Randomized Phase II trial of Gemcitabine Plus TH-302 Versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 33(13):1475\u20131481","journal-title":"J Clin Oncol"},{"key":"3256_CR34","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Melichar B (2016) MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). In ASCO Meeting Abstracts, vol 34, p 4007.","DOI":"10.1200\/JCO.2016.34.15_suppl.4007"},{"key":"3256_CR35","doi-asserted-by":"crossref","unstructured":"Tap W, Papai Z, Van Tine B, Attia S, Ganjoo K, Jones R, Schuetze S, Reed D, Chawla S, Riedel R, Krarup-Hansen A, Italiano A, Hohenberger P, Grignani G, Cranmer L, Alcindor T, Lopez-Pousa A, Pearce T, Kroll S, Schoffski P. Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): study TH-CR-406\/SARC021. Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7\u201311, 2016; Copenhagen","DOI":"10.1093\/annonc\/mdw388.01"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3256-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:41:49Z","timestamp":1589733709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,25]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3256-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,25]]}}}